Frontiers in Immunology最新文献

{"title":"Editorial: Nontuberculous mycobacterial pulmonary disease: immunopathogenesis and immunological risk factors.","authors":"Edward D Chan, Veronica Schmitz","doi":"10.3389/fimmu.2025.1582489","DOIUrl":"10.3389/fimmu.2025.1582489","url":null,"abstract":"","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1582489"},"PeriodicalIF":5.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mediating role of biological age in the association between dietary index for gut microbiota and sarcopenia.","authors":"Jingyuan Zhang, Jun Guo, Jing Zhang, Heng Liu, Lin Zhou, Chi Cheng, Hong Cao","doi":"10.3389/fimmu.2025.1552525","DOIUrl":"10.3389/fimmu.2025.1552525","url":null,"abstract":"<p><strong>Background: </strong>Dietary Index of Gut Microbiota (DI-GM) is a newly proposed comprehensive metric for assessing dietary quality in relation to gut microbiota composition. Alterations in muscle structure are closely linked to DNA methylation-based biological age assessments and individual dietary patterns. However, a systematic investigation of the interrelationships among DI-GM, biological age, and sarcopenia remains lacking. We hypothesize that consuming foods beneficial to the gut microbiota may help mitigate the risk of sarcopenia by slowing the aging process.</p><p><strong>Methods: </strong>This study analyzed data from NHANES 2007-2018. DI-GM was calculated using two 24-hour dietary recall datasets. Sarcopenia was assessed via dual-energy X-ray absorptiometry (DXA). The association between DI-GM and sarcopenia was evaluated using multivariate logistic regression, subgroup analysis, and restricted cubic splines. This study also investigated the potential mediating effects of three biological age indicators: the Klemera-Doubal Method (KDM), PhenoAge, and Homeostatic Dysregulation (HD).</p><p><strong>Results: </strong>An increase in DI-GM score was significantly associated with a reduced risk of sarcopenia (OR: 0.87, 95% CI: 0.82-0.94).The risk of sarcopenia was significantly lower in the highest quartile group (Q3) (OR: 0.25, 95% CI: 0.11-0.58). The three biological age-related indicators (KDM, PA, and HD) partially mediated the association between DI-GM and sarcopenia, with PhenoAge showing the highest mediation proportion at 30.6%.</p><p><strong>Conclusion: </strong>A higher DI-GM score was significantly associated with a reduced risk of sarcopenia. PhenoAge, HD, and KDM demonstrated significant mediating effects, with PhenoAge showing the highest mediation proportion.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1552525"},"PeriodicalIF":5.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies.","authors":"Xiaowen Han, Jiayi Zhang, Weidong Li, Xiaodong Huang, Xueyan Wang, Bofang Wang, Lei Gao, Hao Chen","doi":"10.3389/fimmu.2025.1512509","DOIUrl":"10.3389/fimmu.2025.1512509","url":null,"abstract":"<p><p>Immunotherapy has emerged as a preeminent force in the domain of cancer therapeutics and achieved remarkable breakthroughs. Nevertheless, the high resistance has become the most substantial impediment restricting its clinical efficacy. Beta-2 microglobulin (B2M), the light chain of major histocompatibility complex (MHC) class I, plays an indispensable part by presenting tumor antigens to cytotoxic T lymphocytes (CTLs) for exerting anti-tumor effects. Accumulating evidence indicates that B2M mutation/defect is one of the key mechanisms underlying tumor immunotherapy resistance. Therefore, elucidating the role played by B2M and devising effective strategies to battle against resistance are pressing issues. This review will systematically expound upon them, aiming to provide insight into the potential of B2M as a promising target in anticancer immune response.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1512509"},"PeriodicalIF":5.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Targeting mitochondrial damage: shining a new light on immunotherapy.","authors":"Wenjuan Zeng, Menghui Wang, Yuxin Zhang, Taicheng Zhou, Zhen Zong","doi":"10.3389/fimmu.2025.1591209","DOIUrl":"https://doi.org/10.3389/fimmu.2025.1591209","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fimmu.2024.1432633.].</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1591209"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of monocytes and macrophages in idiopathic inflammatory myopathies: insights into pathogenesis and potential targets.","authors":"Shinji Izuka, Toshihiko Komai, Yumi Tsuchida, Haruka Tsuchiya, Tomohisa Okamura, Keishi Fujio","doi":"10.3389/fimmu.2025.1567833","DOIUrl":"10.3389/fimmu.2025.1567833","url":null,"abstract":"<p><p>Idiopathic inflammatory myopathies (IIMs) are heterogeneous autoimmune disorders characterized by muscle inflammation, weakness, and extramuscular manifestations such as interstitial lung disease, skin rash, arthritis, dysphagia, myocarditis and other systemic organ involvement. Although T and B cells have historically been central to the understanding of IIM immunopathology, monocytes and their differentiated progenitor cells, macrophages, are increasingly being recognized as critical mediators of both tissue damage and repair. In subtypes such as dermatomyositis, immune-mediated necrotizing myopathy and antisynthetase syndrome, macrophages infiltrate skeletal muscle and other affected tissues, contributing to inflammation via production of pro-inflammatory cytokines, chemokines, and reactive oxygen species. Dysregulated interferon signaling, mitochondrial stress, and aberrant metabolic states in these cells further perpetuate tissue injury in IIMs. Conversely, certain macrophage subsets can support muscle fiber regeneration and dampen inflammation, underscoring the dual roles these cells can play. Future research into the heterogeneity of monocytes and macrophages, including single-cell transcriptomic and metabolomic approaches, will help clarify disease mechanisms, identify biomarkers of disease activity and prognosis, and guide novel therapeutic strategies targeting these innate immune cells in IIM.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1567833"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ETS-1 in tumor immunology: implications for novel anti-cancer strategies.","authors":"SiYu Wang, Lei Wan, XiaoJun Zhang, HaoXiang Fang, MengYu Zhang, Feng Li, DaWei Yan","doi":"10.3389/fimmu.2025.1526368","DOIUrl":"10.3389/fimmu.2025.1526368","url":null,"abstract":"<p><p>ETS-1, a key member of the Erythroblast Transformation-Specific (ETS) transcription factor family, plays an important role in cell biology and medical research due to its wide expression profile and strong transcriptional regulation ability. It regulates fundamental biological processes, including cell proliferation, differentiation, and apoptosis, and is involved in tumorigenesis and metastasis, promoting malignant behaviors such as angiogenesis, matrix degradation, and cell migration. Given the association between ETS-1 overexpression and the aggressive characteristics of multiple malignancies, it represents a promising therapeutic target in cancer treatment. This study aims to systematically analyze the role of ETS-1 within the tumor immune microenvironment, elucidating its mechanisms in cancer initiation, progression, and metastasis. It also investigates the differential expression of ETS-1 across tumor tissues and adjacent normal tissues, exploring its potential as a molecular marker for tumor diagnosis and prognosis.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1526368"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac autoantibodies promote a fibrotic transcriptome and reduced ventricular recovery in human myocarditis.","authors":"Jennifer M Myers, Clayton Sandel, Kathy Alvarez, Lori Garman, Graham Wiley, Courtney Montgomery, Patrick Gaffney, Stavros Stavrakis, DeLisa Fairweather, Katelyn A Bruno, Yan Daniel Zhao, Leslie T Cooper, Madeleine W Cunningham","doi":"10.3389/fimmu.2025.1500909","DOIUrl":"10.3389/fimmu.2025.1500909","url":null,"abstract":"<p><p>Myocarditis leads to dilated cardiomyopathy (DCM) with one-third failing to recover normal ejection fraction (EF 50%). Our previous studies have supported a Th17 autoimmune pathogenesis where IL17A and IL-6 are elevated in myocarditis patients who do not recover normal EF. In the non-recovered group, autoantibody mechanisms of pathogenesis in myocardial injury and systolic dysfunction are not fully understood. Furthermore, in our myocarditis cohort, cardiac myosin (CM) autoantibodies (AAbs) were elevated and cross-reactive with the β-adrenergic receptor (βAR). Here we studied cross-reactive CM/βAR serum AAbs and human myocarditis-derived monoclonal antibodies (mAbs) to define their potential pathogenic mechanisms and to identify unique human CM epitopes associated with non-recovery in a longitudinal (n=41) cohort. Elevated CM IgG AAbs in the non-recovered phenotype correlated with reduced EF and poor outcomes. Human CM epitopes unique to the non-recovered phenotype shared strong amino acid sequence homology with extracellular loops of βARs and supported molecular mimicry and cross-reactivity between CM and βAR. Myocarditis-derived IgG and human mAb 2C.4 activated protein kinase A (PKA) in an IgG, CM, and βAR-dependent manner in H9c2 heart myoblast cell line, and transcriptomic analysis revealed mAb 2C.4 induced fibrosis pathways which were highly similar pathways seen with isoproterenol, a beta receptor agonist. Our data translate into new mechanistic insights from our small longitudinal group of myocarditis/DCM patients and into potential therapeutic targets and biomarkers for future studies.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1500909"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restoring immune tolerance in pre-RA: immunometabolic dialogue between gut microbiota and regulatory T cells.","authors":"Anqi Gao, Ruihe Wu, Yanfei Mu, Ruqing Jin, Saixin Jiang, Chong Gao, Xiaofeng Li, Caihong Wang","doi":"10.3389/fimmu.2025.1565133","DOIUrl":"10.3389/fimmu.2025.1565133","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a complex chronic autoimmune disease that remains incurable for most patients. With advances in our understanding of the disease's natural history, the concept of pre-RA has emerged as a window of opportunity to intervene before irreversible joint damage occurs. Numerous studies have indicated that the key step driving autoimmunity in early pre-RA lies at an extra-articular site, which is closely related to the regulatory T (Treg) cell-established immune tolerance to the gut microbiota. The intricate immunometabolic crosstalk between Treg cells and the gut microbiota is beginning to be understood, with the re-recognition of Treg cells as metabolic sensors in recent years. In the future, deciphering their immunometabolic dialogue may help to elucidate the underlying mechanisms of pre-RA. Identifying novel biological pathways in the pre-RA stage will bring insights into restoring immune tolerance, thereby potentially curing or preventing the onset of RA.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1565133"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgE autoantibodies to nuclear antigens in patients with different connective tissue diseases: re-evaluation and novel findings.","authors":"Kathrin Kramer, Ann-Christin Pecher, Jörg Henes, Reinhild Klein","doi":"10.3389/fimmu.2025.1483815","DOIUrl":"10.3389/fimmu.2025.1483815","url":null,"abstract":"<p><strong>Introduction: </strong>Connective tissue diseases (CTD) are characterised by the overproduction of multiple autoantibodies, especially antinuclear antibodies (ANA) of the IgG type. Meanwhile, also IgE autoantibodies have been described. The aim was therefore, to establish an ELISA for the demonstration of IgE autoantibodies to SSA/Ro, SSB/La, RNP proteins and dsDNA in sera from patients with systemic lupus erythematosus (SLE), Sjoegren's syndrome (SS), and mixed connective tissue disease (MCTD) to investigate their frequency and clinical relevance.</p><p><strong>Methods: </strong>Serum samples from 110 patients with SLE, 118 patients with SS, 41 patients with MCTD, and 73 controls were analysed by ELISA for IgE autoantibodies against dsDNA, SSA/Ro52, and SSA/Ro60, SSB/La, and RNP proteins using recombinant antigens. Patients were assessed for different clinical manifestations.</p><p><strong>Results: </strong>In SLE and SS, IgE anti-SSA/Ro52-, -SSA/Ro60- and -SSB/La-antibodies showed a significantly higher reactivity than in controls. IgE anti-dsDNA-antibodies were present in 66% of SLE patients. In SLE, there was a correlation of IgE anti-dsDNA- and -anti-SSA/Ro52-antibodies with disease activity and cutaneous manifestation. Neither IgE anti-SSA/Ro- nor -anti-SSB/La-antibodies were associated with distinct clinical manifestations in SS. Also, anti-RNP-antibodies were found to be of the IgE type (up to 90% in MCTD and 70% in SLE). In MCTD, IgE anti-Sm/RNPB- and -anti-RNP68-antibodies correlated with pulmonary manifestations. IgE anti-dsDNA- but not the other IgE autoantibodies decreased under immunosuppressive therapy.</p><p><strong>Conclusion: </strong>IgE anti-SSA/Ro-, -SSB/La-, -RNP-, and -dsDNA antibodies show a high frequency and specificity for the prevailing CTD. We confirmed an association of anti-dsDNA and anti-SSA/Ro52 antibodies with disease activity in SLE. In MCTD, there was an association of anti-Sm/RNP B and -RNP68 antibodies with pulmonary disorder.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1483815"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023.","authors":"Xiaoyan Chang, Chenghao Wang, Fei Wang, Linyou Zhang","doi":"10.3389/fimmu.2025.1555216","DOIUrl":"10.3389/fimmu.2025.1555216","url":null,"abstract":"<p><strong>Purpose: </strong>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and about half of the patients had mutations in the epidermal growth factor receptor (EGFR) gene. Changes in the tumor microenvironment after EGFR mutation are closely related to tumor progression and treatment efficacy.</p><p><strong>Materials and methods: </strong>We searched the Web of Science Core Collection database to select the articles related to tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation. The countries/regions, institutes, authors, journals, references, and keywords were visualized and analyzed.</p><p><strong>Results: </strong>227 relevant studies were obtained from WoSCC. These articles came from 102 countries and 1179 institutions. After network analysis, it was found that the intensity of USA cooperation with China was the greatest (LS=13), followed by cooperation with South Korea (LS=3) and with Japan (LS=3). A total of 2267 authors participated the all 227 articles. 112 journals were covered, and <i>Frontiers in Oncology</i> published most papers (n=16, 14.3%). A total of 7964 co-cited references are related to TME in NSCLC with EGFR mutation. \"EGFR\" is the keyword with the highest centrality (C=0.31) and first appeared. The keywords that burst in the last 1 year (2022-2023) are \"immunotherapy\", \"mechanism\", \"lung neoplasms\", \"T cells\", and \"multicenter\".</p><p><strong>Conclusion: </strong>Effective drug treatment of advanced NSCLC with EGFR mutations after failure of first-line chemotherapy is one of the hotspots, in which the efficacy of immune checkpoint inhibitors may be the direction of the current and future studies that need to find a breakthrough.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1555216"},"PeriodicalIF":5.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}